PAM
KPTI icon

Premier Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Premier Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,783
Closed -$160K – 134
2019
Q2 		$160K Buy
+1,783
New +$143K 0.04% 142
2019
Q1 		– Sell
-2,002
Closed -$282K – 135
2018
Q4 		$282K Buy
+2,002
New +$338K 0.08% 123

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Premier Asset Management's KPTI Position: Q3 2019 in Review

Premier Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2019, closing a stake of 1,783 shares — an estimated $160K sold.

Premier Asset Management first reported a position in KPTI in Q4 2018 and held it in 2 quarters. The position peaked at $282K in Q4 2018. 106 funds tracked by Wall St. Rank hold KPTI as of Q3 2019.

  • Premier Asset Management reported no remaining Karyopharm Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Premier Asset Management sold 1,783 Karyopharm Therapeutics shares in Q3 2019, an estimated $160K.
  • Premier Asset Management first reported a position in Karyopharm Therapeutics in Q4 2018 and held it in 2 quarters.
  • Premier Asset Management's Karyopharm Therapeutics position peaked at $282K in Q4 2018.
  • 106 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2019.

Based on Premier Asset Management's 13F filing for Q3 2019, filed 1 Nov 2019.